Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 9Breast Neoplasms 5Uterine Cervical Neoplasms 4Gliosarcoma 4Glioma 4Glioblastoma 4Ganglioneuroblastoma 4Pancreatic Neoplasms 3Neuroblastoma 3Vaginal Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Lung Neoplasms 2Glioma, Subependymal 2Ependymoma 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Astrocytoma 2Adenocarcinoma Of Esophagus 2Wilms Tumor 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Thoracic Diseases 1

Interventions

pembrolizumab 1X-Rays 1Taxes 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Congresses as Topic 1Cisplatin 1Carboplatin 1Brachytherapy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Cervical Adenocarcinoma × Congresses as Topic × Clear all
NCT07061977 2026-06-05

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
336 enrolled
Gynecologic

Locally Advanced Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡